RxDoctor Payments Data

James Libby, MD

Urology · Stockbridge, GANPI 1326146507

Payments from drug & device makers

$7,309in general payments, 2019–2025

Across 68 payments — averaging $107.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Metuchen Pharmaceuticals$5K
  • Coloplast$404
  • Astellas Pharma US Inc$388
  • Boston Scientific$263
  • Myovant Sciences Inc.$238
  • Sumitomo Pharma America, Inc.$211
  • plus $513 from 10 others

What the payments were for

  • Speaking & faculty fees$5,00068%
  • Food & beverage$2,12429%
  • Education$1843%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,309 in reported general payments places this provider in the 65th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$431,826
Medicare patients
843
Services billed
56,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide153$2,131,261
OrgovyxRelugolix154$414,433
GemtesaVibegron341$268,477
MyrbetriqMirabegron51$54,122
Tamsulosin Hcl867$12,008
Finasteride606$7,582
Silodosin57$5,896
Alfuzosin Hcl ErAlfuzosin Hcl244$4,309
Ciprofloxacin Hcl755$3,137
Potassium Citrate ErPotassium Citrate63$3,008
NitrofurantoinNitrofurantoin Macrocrystal100$2,805
Testosterone Cypionate57$2,482
Bethanechol Chloride43$2,246
Bicalutamide55$2,225
Doxycycline Hyclate151$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$388$2,185,383204 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$211$682,910495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 369 urology providers in Georgia.

Other urology in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →